Isomorphic Labs, the London-based drug-design company Alphabet spun out of Google DeepMind in 2021, closed a $2.1 billion Series B on May 13, 2026 — the second-largest single fundraise in biotech history, trailing only Altos Labs. Thrive Capital led the round, joined by existing backers Alphabet and GV alongside new investors including sovereign fund MGX, Singapore’s Temasek, CapitalG, and the UK’s Sovereign AI Fund. It is a striking vote of confidence for a company that, four and a half years after launch, has yet to put a single drug into human testing.
From Protein Folding to Drug Design
Isomorphic’s pedigree is the reason investors are willing to write nine-figure checks before seeing clinical data. The company grew out of AlphaFold, the protein-structure-prediction system that won Isomorphic CEO Demis Hassabis (who remains CEO of Google DeepMind as well) a share of the 2024 Nobel Prize in Chemistry. Isomorphic took that structural-biology breakthrough and built the Isomorphic Labs Drug Design Engine, or IsoDDE, a platform the company says can predict not just how a molecule binds its target but its likely toxicity — the two properties that most often sink drug candidates late and expensively. President Max Jaderberg called the new funding “validation of what we’ve been building out the past four-and-a-half, almost five, years.”
Where the Money Is Going
Isomorphic says it is directing internal development toward oncology, immunology, and inflammation, deliberately targeting what Jaderberg described as “big zero-to-one problems” rather than fast-follower molecules chasing an already-validated target. That is a more ambitious — and riskier — bet than licensing out AI-designed candidates against known biology, since novel targets fail in the clinic more often than validated ones. Hassabis has said the company expects to file its first Investigational New Drug application with regulators by the end of 2026, a timeline that has already slipped from earlier public statements.
The Partnership Backbone
Separate from its own pipeline, Isomorphic has stacked up deals with Novartis, Eli Lilly, and — as of January 2026 — Johnson & Johnson’s Janssen Biotech unit, collaborations collectively reported to be worth as much as $3 billion. Those partnerships fund near-term revenue and validate the platform against partners’ internal chemistry teams, while the company’s own wholly owned pipeline is where Isomorphic is betting its long-term valuation lies. The open question the company has pointedly not answered is whether it will eventually sell off internally discovered assets, license them the way Insilico or Recursion do, or become a fully integrated drug company that markets its own medicines.
The Case for Skepticism
A $2.1 billion round with no disclosed valuation and no drug yet in a human being is, by any normal biotech underwriting standard, an enormous bet on unproven output. Rivals and some biotech investors point out that structure prediction — Isomorphic’s core technical strength — is necessary but not sufficient for drug design; correctly modeling toxicity, pharmacokinetics, and manufacturability in silico remains far less mature than protein folding, and no company, including Isomorphic, has publicly demonstrated an AI system that reliably beats human medicinal chemists on those dimensions. The slipping IND timeline is itself a data point worth taking seriously.
What It Means Going Forward
The fundraise effectively buys Isomorphic several more years of runway to answer the question its investors are betting on: can a model trained to predict protein shapes be extended into a system that reliably designs safe, effective, manufacturable drugs? The end-of-2026 IND filing, if it happens on schedule, will be the first real external checkpoint. Until then, the $2.1 billion is a bet on a scientific pedigree and a platform, not yet on clinical results — and industry watchers, including partners like Lilly and Novartis who have their own AI-discovery bets running in parallel, will be measuring Isomorphic’s actual clinical output against the scale of capital it has now raised.
A Broader Signal for the Industry
The size of the round also matters beyond Isomorphic itself. A $2.1 billion Series B, closed in a single tranche led by a single anchor investor, signals that at least some large pools of capital are still willing to underwrite AI-drug-discovery platforms years before clinical proof, even after a wave of skepticism earlier in the decade about whether AI-native biotechs could translate computational promise into approved medicines. Competing platforms — Recursion, Insilico, Xaira, and a growing list of newer entrants — will likely point to Isomorphic’s raise as evidence that investor appetite for the category remains intact, even as each company’s actual clinical progress varies widely. Whether that capital availability persists past 2026 may depend heavily on whether Isomorphic’s promised IND filing materializes on schedule or slips again.
